Liraglutide subcutaneous injection

Form: Subcutaneous injection/Pre filled Pen

Strength: 6 mg/mL solution

Reference Brands: Victoza(US & EU)

Category: Diabetes

Liraglutide injection, approved by both the FDA and EMA, is prescribed for type 2 diabetes, weight management, and cardiovascular risk reduction. Marketed under brand names like Victoza® and Saxenda®, it requires a prescription and proper medical supervision. In the U.S., it carries a boxed warning for thyroid C-cell tumors, while the EU mandates PSURs and risk management plans. Cold-chain storage and pharmacovigilance are required in both regions. For regulatory-compliant sourcing and global distribution of liraglutide injection, visit PharmaTradz.com.